Key financial indicators such as net sales, operating income, and net income are disclosed, with explanations of segment-wise sales and growth drivers (3L product lineup, drivers of pharmaceutical business revenue). Includes outlook, progress, and IFRS consolidated results among related information.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4523","jir_company_name":"Eisai Co., Ltd. (Eisai Co., Ltd.)","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-03","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4523-20260803-03.pdf","jir_short_summary":"Key financial indicators such as net sales, operating income, and net income are disclosed, with explanations of segment-wise sales and growth drivers (3L product lineup, drivers of pharmaceutical business revenue). Includes outlook, progress, and IFRS consolidated results among related information.","jir_summary":"### Overview of Performance\nBased on IFRS consolidated results for this quarter, the trends in net sales, operating income, and core operating income are reported. Growth in the pharmaceutical business centered on the 3L products is contributing, with expansion of the pharmaceutical business and contributions from new products highlighted as factors driving sales mix. The increases in sales and profits and future outlook, along with the contributions by major segments, are shown with charts.\n\n### Impact on Shareholders \/ Outlook\nExplains the full-year outlook, progress for 2026, and important IR information (IFRS consolidated results, segment contributions, R&D expense levels, impacts of M&A and partnerships). For investors, notes on the sustainability of growth drivers, profitability improvement, and capital policy directions are provided.","jir_financial_highlights":"Net Sales: Unknown (YoY +16% (based on IFRS consolidated results section))\nOperating income: Unknown (Projected YoY increase of around +19% (with charts and factor explanations))\nCore operating income: Unknown (YoY improvement around +33% described)","jir_category":"","jir_hashtags":"#Eisai, #IR, #JapanStocks","jir_key_figures":"Net sales: Unknown\nOperating income: Unknown\nCore operating income: Unknown","jir_meta_title":"\u3010Eisai\u3011FY2026 Q1 Financial Summary | Revenue, Profit Trends and Growth Drivers","jir_meta_description":"In Eisai's FY2026 Q1 Financial Summary, explanations cover net sales, operating income, core operating income, IFRS consolidated results, segment contributions, and growth drivers (3L products and pharmaceutical business). Outlook is also discussed.","jir_og_title":"Eisai Financial Summary | Q1 2026","jir_og_description":"Eisai's FY2026 Q1 Financial Summary explains IFRS consolidated results, key indicators, segment contributions, and growth factors.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Sales Trend\", \"jir_chart_json_data\": \"Unknown\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"Unknown\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segmented Net Sales\", \"jir_chart_json_data\": \"Unknown\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Profit Margin Analysis\", \"jir_chart_json_data\": \"Unknown\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Forecast vs Actual\", \"jir_chart_json_data\": \"Unknown\"}]","ir_related_company":7482,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-93453","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n